Evaluation of the MP Diagnostics HTLV Blot 2.4

MP Biomedicals, LLC600 enrolled

Overview

The purpose of this study is: 1. To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4. 2. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.

This is a retrospective study designed to assess the validity and reproducibility of the MP Diagnostics IVD device, the HTLV Blot 2.4 (MP Blot), in various populations. The study will be conducted at three geographical distinct locations. The validity of the MP Blot will be assessed by calculating the following: 1. Percent negative agreement with CDPHL Algorithm on 200 EIA negative specimens 2. Percent positive agreement with CDPHL Algorithm on 200 EIA repeat reactive specimens The sensitivity of the MP Blot will be evaluated by testing 200 known positive specimens. The study will be performed using three product lots at three clinical sites. The reproducibility of the MP Blot will be assessed by testing two replicates of a three member panel at three clinical testing sites with each of three lots of product over multiple days by three operators.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

HTLV-I Infections HTLV-II Infections Human T-lymphotropic Virus 1 Human T-lymphotropic Virus 2 HTLV I Associated T Cell Leukemia Lymphoma HTLV I Associated Myelopathies

Interventions

CDPHL AlgorithmOTHER

Supplemental testing algorithm performed by the CDPHL.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * EIA Negative Population 1. Male or female 2. Completion of a health history evaluation for routine donor screening 3. Willing and able to provide informed consent 4. Negative screening assay results for all ARC screening assays * EIA Repeat Reactive Population 1. Male or female 2. Completion of a health history evaluation for routine donor screening 3. Willing and able to provide informed consent 4. Previous RR result by bioMerieux ELISA, Abbott EIA, and / or Abbott ChLIA PRISM * Known Positive Population 1. Male or female 2. Willing and able to provide informed consent 3. Previous reactive screening test using either the bioMerieux ELISA, the Abbott EIA or the Abbott ChLIA PRISM, followed by supplemental testing Exclusion Criteria: * EIA Negative Population 1. Inadequate sample volume for testing 2. Unable to provide samples that meet the sample suitability requirements for testing 3. Positive screening result for any infectious disease tested by ARC * EIA Repeat Reactive Population 1. Inadequate sample volume for testing 2. Unable to provide samples that meet the sample suitability requirements for testing 3. Positive result for HIV, HBV, HCV, or any other infectious disease * Known Positive Population 1. Unwilling or unable to provide informed consent 2. Unable to provide adequate sample volume for testing 3. Unable to provide samples that meet the sample suitability requirements for testing 4. Positive result for HIV

Locations (2)

California Department of Public Health

Richmond, California, United States

LABS, Inc

St Louis, Missouri, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.